Use of experimental vaccinations

Traditional vaccines, such as whole pathogen and subunit vaccines introduce dead or weakened pathogens to stimulate a direct immunological response.

Nucleic Acid Vaccines, such as mRNA and viral vector vaccines work differently. They introduce genetic material to encode the cellular production of an antigen response without exposure to the target pathogen and both are types of gene-based vaccines.

In relation to Covid-19 vaccinations, Moderna and Pfizer are examples of mRNA vaccines; AstraZeneca and Johnson & Johnson are viral vector vaccines – these four ‘vaccines’ are actually injections, in that they do not include the virus, and they have never been used before as vaccinations – hence the complete lack of medium and long term evaluation.

As stated, whilst both are new vaccine technologies, mRNA gene-based vaccines have never been used in humans before. Although phase III trials are complete, participants continue to be monitored until 2022-2023. The vaccines being rolled out are therefore novel, with only limited short term and no longterm safety data available.

Clinicians practising within the NHS are obliged to do two things when administering a vaccine:

• To do no harm
• And to obtain the free and informed consent of those being vaccinated

The provision of information to the public has been inadequate and misleading and has not informed the public of the material risks. Adverse event data is being collected by the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Reporting Scheme. Sadly, it seems that not many affected patients know of its existence and it is estimated that the figures may only represent between 1% and 10%.

There have been 1,625 reported fatalities (September 2021). There have been over a million adverse events recorded in the UK via the Yellow Reporting Scheme including incidences of the following: Anaphylaxis; blood clots with concurrent low platelets; Capillary Leak Syndrome; Bell’s Palsy; Menstrual Disorders and unexpected bleeding; Myocarditis and Pericarditis and Guillain-Barre Syndrome.

The 1976 emergency vaccine for Swine Flu was suspended on safety grounds after at least 25 people died from vaccine reactions. Other estimates put the death toll at 32 people, while about 500 others later suffered from Guillain-Barre syndrome.

Does this beg the question as to why the rollout has continued, alongside an unrelenting and unquestioning advertisement and coercion campaigns by PHE and the NHS?

Quantitative Data Analyst, Joel Smalley, recently conducted a study on mortality data during the vaccine rollout period. He notes that around the second week in December 2020, a new ‘mortality series’ begins, which does not fit the previous patterns seen in Spring and Autumn of that year. This peak in deaths coincides with the mass roll-out of the novel vaccinations on a vulnerable population.

It is also important to note that the same phenomenon is apparent in many countries regardless of location, season and intervention policies. Whilst we cannot infer causation from correlation, would it not be negligent not to investigate further? It appears every effort has been made to maximise reported COVID-19 mortality while minimising, or even denying, any vaccine-related mortality.